PEDIATRIC CHTN--AIDS CANCER RESEARCH

儿科 CHTN--艾滋病癌症研究

• 批准号: 6344281
• 负责人: STEPHEN J QUALMAN
• 金额: $ 84.44万
• 依托单位: RESEARCH INST NATIONWIDE CHILDREN'S HOSP
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-01-01 至 2006-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6344281
• 关键词: cancer registry /resource; cooperative study; human tissue; leukemia; microarray technology; neoplasm /cancer genetics; pediatric neoplasm /cancer; tissue resource /registry

DESCRIPTION: (Provided by Applicant) Molecular biology combined with pathology is fast becoming the standard of practice in pediatric cancer diagnosis within the Pediatric Cooperative Human Tissue Network (CHTN), our working hypothesis is the centralized tracking, procurement/preparation and dispersal of pediatric tissue specimens facilitate biomedical and molecular biologic research. Pediatric cancer remains the number one cause of death due to disease in children, and studies of its genetic mechanisms may serve as a model for studies of adult cancers. Our SPECIFIC AIMS are fourfold: 1) to expand pediatric tumor procurement working with the newly-unified Children?s Oncology Group (C.O.G.), 2) to enhance processing of tissues via new technologies to facilitate molecular research, 3) to initiate new informed consent procedures facilitating linkage to clinical outcomes, and 4) to expand networking of rare specimens (leukemias, adolescent cancers) through the CHTN mechanisms to increase investigator access. To achieve these aims, the Pediatric CHTN has newly partnered with the C.O.G. which should provide new access to 94 percent of pediatric cancers in North America - with up to two-thirds of patients joining clinical protocols. The Pediatric CHTN will offer new technologies for processing of pediatric cancer tissues - "RNA Later" solution in kits, nucleic acid extractions, Laser Capture Microscopy, and tissue microarrays to facilitate molecular biologic studies. The Pediatric CHTN and C.O.G. will also partner to place informed consents on surgical or other procedural consent forms -so that "up-front" informed consent may improve patient entry onto clinical protocols (goal >90 percent) with its linkage to clinical follow-up. Finally, the Pediatric CHTN and C.O.G. will partner to improve investigator access via the CHTN to cancers which are rare to obtain for molecular studies (adolescent, cancers, leukemias). Achievement of these aims should help the Pediatric CHTN to further facilitate pediatric cancer research in the new millennium.

描述：（申请人提供） 分子生物学与病理相结合正在迅速成为标准 小儿诊断的小儿合作诊断 组织网络（CHTN），我们的工作假设是集中式跟踪， 小儿组织标本的采购/制备和分散促进 生物医学和分子生物学研究。小儿癌仍然是 由于儿童疾病而导致的第一名死亡原因及其研究 遗传机制可以作为研究成人癌症的模型。我们的 具体目的是四倍：1）扩大小儿肿瘤采购的工作 与新统一的儿童肿瘤学小组（C.O.G.），2）增强 通过新技术处理组织以促进分子研究， 3）启动新的知情同意程序，以促进与 临床结果和4）扩大稀有标本的网络（白血病， 通过CHTN机制增加研究者的青少年癌 使用权。为了实现这些目标，儿科CHTN与 C.O.G.应该为94％的儿科癌症提供新的机会 北美 - 多达三分之二的患者加入临床方案。 小儿CHTN将提供用于处理小儿的新技术 癌组织 - “ RNA后来”溶液在试剂盒，核酸提取，激光 捕获显微镜和组织微阵列以促进分子生物学 研究。小儿CHTN和C.O.G.还将伙伴放置知情 同意外科手术或其他程序同意书的同意 - “前期” 知情同意可以改善患者进入临床方案（目标> 90 百分比）与临床随访联系。最后，小儿CHTN 和C.O.G.将合作通过CHTN来改善调查员进入癌症 对于分子研究很少获得的（青春期，癌症， 白血病）。这些目标的实现应有助于小儿CHTN 进一步促进了新千年的小儿癌症研究。